Iron Deficiency Injectable Market Report 2026
Global Outlook – By Type (Iron Dextran, Ferric Carboxymaltose), By Branded or Generics (Branded, Generics), By Application (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Applications), By End User (Hospitals, Homecare, Specialty Clinics, Other End Users) - Market Size, Trends, Strategies, and Forecast to 2030
Iron Deficiency Injectable Market Overview
• Iron Deficiency Injectable market size has reached to $15.22 billion in 2025 • Expected to grow to $25.69 billion in 2030 at a compound annual growth rate (CAGR) of 11.3% • Growth Driver: Rising Prevalence Of Pcos Fuels Demand For Iron Deficiency Injectables • Market Trend: Companies Introduce Innovative Iron Deficiency Therapies Like Injectafer To Expand Market Presence • North America was the largest region in 2025.What Is Covered Under Iron Deficiency Injectable Market?
Iron deficiency refers to a condition where the body lacks adequate iron, leading to decreased production of red blood cells and hemoglobin. Iron deficiency injectables refer to injectable medications or solutions used to treat iron deficiency. These injectable forms of iron allow for direct delivery of the iron into the bloodstream, bypassing the digestive system. The main types of iron deficiency injectables are iron dextran, iron sucrose and ferric carboxymaltose. Iron dextran is a complex of iron and a carbohydrate called dextran. The various types of branded or generics are branded, generics that are used in various applications such as chronic kidney disease, inflammatory bowel disease, cancer and others and also by various end users such as hospitals, homecare, specialty clinics and others.
What Is The Iron Deficiency Injectable Market Size and Share 2026?
The iron deficiency injectable market size has grown strongly in recent years. It will grow from $15.22 billion in 2025 to $16.74 billion in 2026 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to high prevalence of iron deficiency anemia, limited efficacy of oral iron therapies, increasing chronic kidney disease cases, growth in hospital-based infusion treatments, wider clinical acceptance of injectable iron.What Is The Iron Deficiency Injectable Market Growth Forecast?
The iron deficiency injectable market size is expected to see rapid growth in the next few years. It will grow to $25.69 billion in 2030 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to rising geriatric population, increasing cancer and IBD prevalence, expansion of homecare infusion services, improved safety profiles of newer formulations, growing healthcare access in emerging markets. Major trends in the forecast period include rising preference for injectable iron over oral therapies, increasing use in chronic kidney disease management, growth of day-care and short-duration infusion protocols, expansion of generic injectable iron products, higher adoption in oncology and chronic disease treatment.
Global Iron Deficiency Injectable Market Segmentation
1) By Type: Iron Dextran, Ferric Carboxymaltose 2) By Branded or Generics: Branded, Generics 3) By Application: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Applications 4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users Subsegments: 1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran 2) By Ferric Carboxymaltose: Injectafer, FerinjectWhat Is The Driver Of The Iron Deficiency Injectable Market?
The increasing prevalence of polycystic ovary syndrome (PCOS) is expected to propel the growth of the iron deficiency injectables market going forward. Polycystic ovary syndrome (PCOS) is a common hormonal disorder that affects people with ovaries, primarily women of reproductive age. Polycystic ovary syndrome (PCOS) leads to iron overload, which results in excessive blood loss during menstruation and makes patients anemic, which can be cured by injectable iron deficiency medications. For instance, in June 2023, according to the World Health Organization, a US-based specialized health agency, globally, polycystic ovary syndrome (PCOS) affects an estimated 8–13% of reproductive-aged women, among whom 70% remain undiagnosed. Therefore, the prevalence Of polycystic ovary syndrome (PCOS) is driving the growth of the iron deficiency injectables industry.Key Players In The Global Iron Deficiency Injectable Market
Major companies operating in the iron deficiency injectable market are Daiichi Sankyo Company Limited, Pfizer Inc., Fresenius Medical Care, AbbVie Inc., Bayer AG, AstraZeneca Plc, GSK Plc, Teva Pharmaceutical Industries Ltd., Mylan N.V., B Braun Medical Inc., Sandoz, Fresenius Kabi AG, AMAG Pharmaceuticals Inc., Luitpold Pharmaceuticals Inc., Akebia Therapeutics Inc., Covis Pharma GmbH , Keryx Biopharmaceuticals Inc., Rockwell Medical Inc., American Regent Inc.
This chart is for illustrative purposes; the full report includes a detailed competitor analysis and comprehensive overview of the top 10 companies in the market.
This chart maps companies by product innovation and brand strength, with bubble size indicating relative revenue, helping identify market leaders, challengers, and niche players. This is an illustrative chart; the full report provides a complete and accurate competitive analysis.
Explore how leading companies compare across key metrics in our report Get Report
Global Iron Deficiency Injectable Market Trends and Insights
Major companies operating in the iron deficiency injectables market are developing new therapies, such as INJECTAFER, to sustain their position in the market. For instance, in June 2023, Daiichi Sankyo Company, a US-based healthcare company and American Regent Inc., a US-based injectables manufacturer, launched INJECTAFER (ferric carboxymaltose injection) for iron deficiency, which the Food And Drug Administration, a US-based government agency, approved. This is the first and only intravenous iron replacement therapy for adult patients with chronic and progressive heart failure to receive FDA approval. More than 40 clinical trials involving more than 8,800 participants from different countries were examined with INJECTAFER. This latest approval builds on INJECTAFER's successful and demonstrated use in these patients, including adult and pediatric patients with iron-deficient anemia and heart failure.What Are Latest Mergers And Acquisitions In The Iron Deficiency Injectable Market?
In November 2024, SteinCares, a health-focused company, partnered with Pharmacosmos A/S to expand its portfolio of iron-deficiency therapies in the region. With this partnership, SteinCares and Pharmacosmos aim to increase patient access to advanced intravenous iron treatments and strengthen the availability of evidence-based solutions for iron deficiency and iron-deficiency anemia. Pharmacosmos A/S is a Denmark-based pharmaceutical company specializing in iron therapy and hematology solutions.
Regional Outlook
North America was the largest region in the iron deficiency injectable market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.Need data for a specific geography? Request Regional Data
What Defines the Iron Deficiency Injectable Market?
The iron deficiency injectable market consists of sales of ferumoxide, sodium ferric gluconate and iron gluconate. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This chart presents market attractiveness based on a quantitative evaluation of growth, competition, strategic alignment, and risk, offering a clear view of opportunity areas for decision-making. This chart is for illustrative purposes; the full report contains the complete analysis.
This chart highlights the Total Addressable Market (TAM) by estimating the maximum revenue opportunity using an assumption-driven approach, supporting strategic planning and opportunity sizing across markets. The chart is illustrative; the full report provides a more comprehensive analysis.
Access full TAM calculations and growth projections in our report Get Report
What Key Data and Analysis Are Included in the Iron Deficiency Injectable Market Report 2026?
The iron deficiency injectable market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the iron deficiency injectable industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Iron Deficiency Injectable Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $16.74 billion |
| Revenue Forecast In 2030 | $25.69 billion |
| Growth Rate | CAGR of 11.3% from 2026 to 2030 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2030 |
| Segments Covered | Type, Branded or Generics, Application, End User |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain |
| Key Companies Profiled | Daiichi Sankyo Company Limited, Pfizer Inc., Fresenius Medical Care, AbbVie Inc., Bayer AG, AstraZeneca Plc, GSK Plc, Teva Pharmaceutical Industries Ltd., Mylan N.V., B Braun Medical Inc., Sandoz, Fresenius Kabi AG, AMAG Pharmaceuticals Inc., Luitpold Pharmaceuticals Inc., Akebia Therapeutics Inc., Covis Pharma GmbH , Keryx Biopharmaceuticals Inc., Rockwell Medical Inc., American Regent Inc. |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |